{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:53:50Z","timestamp":1787068430332,"version":"build-2736575974"},"reference-count":5,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI175821"],"award-info":[{"award-number":["R21AI175821"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI140287"],"award-info":[{"award-number":["R01AI140287"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cefiderocol is a novel antibiotic used to treat multidrug\u2010resistant bacterial infections. However, there is limited data on its effectiveness for ventriculitis. The objective of this study was to evaluate cefiderocol concentrations in both serum and cerebrospinal fluid (CSF) during the treatment of ventriculitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      A 54\u2010year\u2010old patient with carbapenem\u2010resistant\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      ventriculitis was given cefiderocol intravenously 2\u2009g every 6\u2009h (each dose administered over 3\u2009h). Serial samples were obtained over a dosing interval at steady state, and cefiderocol concentrations in serum and CSF were assayed by liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS). Cefiderocol serum concentration\u2010time profile was characterized by a one\u2010compartment model with zero\u2010order input. Penetration into CSF was estimated as the CSF AUC\/unbound serum AUC ratio.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Observed total serum concentrations ranged between 24.6 and 76.7\u2009mg\/L, while CSF concentrations were approximately 10.0\u2009mg\/L. The AUC\n                      <jats:sub>0\u20136<\/jats:sub>\n                      of the free drug in serum and CSF were 181.6 and 60.2\u2009mg\u2009h\/L, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We observed minimal fluctuation of cefiderocol concentrations in CSF, questioning the conventional reliance on CSF\/serum area under the curve (AUC) ratio as a measure of CNS penetration. Our experience suggests that a single CSF concentration (random or trough) could be directly compared to the minimum inhibitory concentration, offering a potentially simpler approach to evaluate dosing adequacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.4632","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T08:24:11Z","timestamp":1733300651000},"page":"66-69","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics of cefiderocol in a patient with carbapenem\u2010resistant\n                    <i>Acinetobacter baumannii<\/i>\n                    ventriculitis: A\u00a0case report"],"prefix":"10.1002","volume":"45","author":[{"given":"Natalie A.","family":"Finch","sequence":"first","affiliation":[{"name":"Department of Pharmacy Houston Methodist Hospital  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Granillo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine Houston Methodist Hospital  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Pouya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research University of Houston College of Pharmacy  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Bhimraj","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine Houston Methodist Hospital  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine Houston Methodist Hospital  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-5376","authenticated-orcid":false,"given":"Vincent H.","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research University of Houston College of Pharmacy  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106723"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107193"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01063-5"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(05)70171-7"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac248"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.4632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:23:50Z","timestamp":1761049430000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.4632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/phar.4632"],"URL":"https:\/\/doi.org\/10.1002\/phar.4632","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"2024-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}